Avadel Pharmaceuticals plc
AVDL
$14.20
$0.201.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 68.13M | 52.51M | 50.41M | 50.03M | 41.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.13M | 52.51M | 50.41M | 50.03M | 41.50M |
| Cost of Revenue | 6.37M | 5.58M | 4.81M | 6.16M | 2.79M |
| Gross Profit | 61.76M | 46.93M | 45.60M | 43.87M | 38.72M |
| SG&A Expenses | 48.62M | 45.58M | 44.62M | 40.39M | 47.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.25M | 55.51M | 53.71M | 50.35M | 54.25M |
| Operating Income | 8.88M | -3.00M | -3.30M | -327.00K | -12.74M |
| Income Before Tax | 6.50M | -4.84M | -4.96M | -2.54M | -14.33M |
| Income Tax Expenses | -3.17M | 78.00K | 80.00K | 88.00K | -509.00K |
| Earnings from Continuing Operations | 9.67M | -4.92M | -5.04M | -2.63M | -13.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.67M | -4.92M | -5.04M | -2.63M | -13.82M |
| EBIT | 8.88M | -3.00M | -3.30M | -327.00K | -12.74M |
| EBITDA | 9.95M | -2.18M | -2.63M | 708.00K | -12.30M |
| EPS Basic | 0.10 | -0.05 | -0.05 | -0.03 | -0.14 |
| Normalized Basic EPS | 0.04 | -0.03 | -0.03 | -0.02 | -0.10 |
| EPS Diluted | 0.10 | -0.05 | -0.05 | -0.03 | -0.14 |
| Normalized Diluted EPS | 0.04 | -0.03 | -0.03 | -0.02 | -0.10 |
| Average Basic Shares Outstanding | 96.73M | 96.60M | 96.40M | 96.30M | 96.15M |
| Average Diluted Shares Outstanding | 99.09M | 96.60M | 96.40M | 96.30M | 96.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |